DAVID W GRYSKA
CIK 1202335 · Executive Vice President, CFO · last filed 2026-08-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.05M
Companies
11
Total Filings
118
Lifetime Open-Market Net
-$23.62M
Filer Profile
Reported Address
749 N MARY AVESUNNYVALE, CA 94085
Related Filers
CELGENE CORP /DE/ — 22 joint filings, latest 2010-07-15
INCYTE CORP — 18 joint filings, latest 2018-07-18
PDL BIOPHARMA, INC. — 16 joint filings, latest 2020-12-31
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FBRX | Director | 0 | $76.99 | $0 | $0 | 7 | 2026-08-27 |
| DFTX | Director | 19,900 | $38.81 | $772.3K | $0 | 1 | 2026-06-15 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Director | 19,851 | $15.00 | $297.8K | $38.9K | 5 | 2025-06-16 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | -$9.71M | 42 | 2023-12-15 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | Director | 0 | $15.25 | $0 | $0 | 7 | 2022-11-21 |
| GW PHARMACEUTICALS PLC (GWPH) Delisted | Director | — | $218.96 | — | $0 | 2 | 2021-02-24 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | Director | 1,387 | — | — | -$925.8K | 14 | 2020-12-31 |
| INCY | Executive Vice President, CFO | 10,235 | $125.31 | $1.28M | -$9.18M | 17 | 2018-07-18 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | — | — | — | $0 | 1 | 2013-05-01 |
| CELGENE CORP /DE/ (CELG) Delisted | Chief Financial Officer | 7,526 | — | — | -$3.84M | 20 | 2010-07-15 |
| COTHERIX INC (CTRX) Delisted | Director | — | — | — | $0 | 1 | 2007-01-10 |
Recent Filings · Page 6 of 12
118 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-07-05 | INCY | Mixed | −280 | -$19.1K | EDGAR |
| 2018-06-12 | PDL BIOPHARMA, INC. (PDLI) Delisted | Grant (A) | +54,348 | $150.0K | EDGAR |
| 2018-05-22 | Seagen Inc. (SGEN) Delisted | Grant (A) | +3,700 | $0 | EDGAR |
| 2018-02-22 | INCY | Mixed | −3,022 | -$259.1K | EDGAR |
| 2018-01-25 | INCY | Grant (A) | — | $0 | EDGAR |
| 2018-01-09 | INCY | Mixed | — | -$101.7K | EDGAR |
| 2017-11-03 | INCY | Mixed | −7,828 | -$836.0K | EDGAR |
| 2017-09-15 | INCY | Tax (F) | −712 | -$87.7K | EDGAR |
| 2017-07-07 | INCY | Grant (A) | +3,517 | $0 | EDGAR |
| 2017-07-05 | INCY | Mixed | — | -$33.9K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.